ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1460

Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
Abstract Number: 0968

Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort
Abstract Number: 0596

Neutrophil Extracellular Traps (NET) Trigger an Enhanced Pro-inflammatory Response in Macrophage Subpopulations in Rheumatoid Arthritis Patients via the Aryl Hydrocarbon Receptor (AhR) Pathway
Abstract Number: 0537

Neutrophil Extracellular Traps as a Biomarker to Predict Outcomes in Lupus Nephritis
Abstract Number: 1803

Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Abstract Number: 0877

Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 0023

New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature
Abstract Number: 0772

New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Abstract Number: 0182

Newly Diagnosed with Inflammatory Arthritis. Development of a Complex Self-management Intervention
Abstract Number: 1528

Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
Abstract Number: 1854

Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions
Abstract Number: 1719

NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
Abstract Number: 0818

NLRP12-associated Autoinflammatory Disease in Chinese Adult Patients: A Single-center Study
Abstract Number: 0429

No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Abstract Number: 0764

No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].